Kite was only in a phase 1/2 trial. No phase 3. Not really further along than us if in a year of so GNBT reports that the mean survival time for the first patients is being extended. I will be very surprised if we have to wait anywhere near 5 years.
Kite was a company that Joe told us to look at. And that was because of the CAR-T connection. Thomas Barnard pointed out several others - don't remember the names.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links